Thu.Apr 21, 2022

article thumbnail

US study finds high rates of unneeded antibiotic prescribing

pharmaphorum

A study has found that there is still a very high level of inappropriate antibiotic prescribing to patients in the US, particularly to older and Black patients. Sifting through data from around seven billion outpatient visits to doctor’s offices, hospital clinics and emergency departments over a seven-year period, the researchers found that almost three-quarters (74%) of antibiotics prescribed to patients aged 65 years or older, and two thirds (64%) to Black patients, were unnecessary.

Hospitals 122
article thumbnail

Tech Innovations: April 2022

Outsourcing Pharma

The latest news on expansions, innovations, awards, and more includes items from Eversana, DHL Supply Chain, X-Chem, Medidata, and other notable companies.

94
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Engagement to partnership: The changing face of patient involvement

pharmaphorum

The era of patient engagement is over. Instead, it’s time to move towards true partnership at every step of the pharma value chain, from R&D to manufacturing. Partnership is the ethos behind UCB’s new patient-centred framework, which provides colleagues in all business functions with a tangible roadmap on how to effectively work with patients. Iris Loew-Friedrich, the organisation’s chief medical officer and head of development, tells pharmaphorum how the initiative will help guide the creat

article thumbnail

Sustainable, biodegradable and Eco- Friendly Packaging: A Paradigm Shift in Healthcare Packaging

Roots Analysis

What is Sustainability and Why is Sustainability Important? The term sustainability is derived from the Latin word sustinere, which means to hold or support. Sustainable packaging is defined as packaging that is safe for individuals, as well as the environment, while meeting all requirements for performance, cost and ease of fabrication. Further, the product should be specially designed in order to minimize usage of raw material and optimize energy use.

article thumbnail

Position Your Pharmacy for Expansion

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

article thumbnail

BioArctic left in the cold as AbbVie abandons Parkinson’s pact

pharmaphorum

One of the leading companies in the bid to bring a new class of alpha-synuclein targeting drugs to market for Parkinson’s disease – AbbVie – is ducking out of the challenge. The pharma company has decided to end its collaboration with Swedish biotech BioArctic on alpha-synuclein-targeting antibody ABBV-0805, which was in early-stage clinical testing, as well as a portfolio of follow-up antibodies.

97
article thumbnail

NICE releases revised guidelines on antidepressants

Pharma Times

The new guidelines focus on key areas of prescription, management of withdrawal and severity of withdrawal symptoms

More Trending

article thumbnail

Leeds health chief issues warning about the risks of missing MMR vaccinations

Pharma Times

The civil servant drew attention to vaccinations falling to lowest level in a decade

article thumbnail

KOL Identification & Mapping Driven By Insights

pharmaphorum

Insights captured from KOL interactions represent a new way to identify and map the KOL landscape in which your brand must thrive. KOL identification and mapping is often driven by quantitative analytics looking at activity across publications, congresses, trials, social channels, and so forth. Although beneficial in many ways, this activity-driven approach by its very nature creates a limited view of KOLs which is based primarily on their past activity.

52
article thumbnail

US meds spending spiked last year, but will fall quickly

pharmaphorum

Prescription drug use in the US soared last year, as might be expected during a pandemic, but is expected to fall back sharply in 2023, according to IQVIA’s latest report on the sector. Overall spending on medicines rose 12% in 2021 to $407 billion, driven by a $29 billion spend on COVID-19 vaccines and medicines. Without that effect the underlying growth was 5%, with rising use of biosimilars offsetting increased use of branded medicines, although IQVIA notes that the pharma sector has de

article thumbnail

GSK workers vote for strike action over “derisory” pay offer

pharmaphorum

Workers at a number of GlaxoSmithKline manufacturing plants in the UK have voted to take industrial action over what the Unite union has described as a “derisory” pay offer. A majority of employees – 86% according to the union – voted yesterday that they would start strike actin within 48 hours unless GSK to raise its 2.75% pay increase, which Unite said is ” a substantial real terms pay cut” given inflation is currently standing at 9% in the UK.

52
article thumbnail

What the FDA's New Dosage Guidance Means for the Future of Clinical Research

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.